Welcome : Guest

Nymox Pharmaceutical Corporation (Canada) - Facts, Figures and Analytical Insights

Abstract

This report presents quick facts about Nymox Pharmaceutical Corporation, which is principally involved in Biopharmaceuticals Business. Illustrated with 54 tables, the report showcases the company's sales performance, key markets and market position as against its competitors operating in the industry.

Code: PCP-40184
Price: $2700
Company Type: Public
Pages: 57
Date: November 2016
Market Data Tables: 54

 NOTE : Select the checkbox below, and click Add to Cart button to add this report to your shopping cart.
Table 1: Nymox Pharmaceutical Corporation’s Sales by Geographic Region Worldwide (2014-2015) in Percentage for United States, and Europe and Others......3
Infectious Disease......5
Table 2: Infectious Disease Drugs Market by Category Worldwide (2015) - Percentage Share Breakdown by Value Sales for Antifungals, Antivirals, Cephalosporins, Macrolides, Penicillins, Quinolones, and Others......5
Table 3: Infectious Disease Market by Segment Worldwide (2015) - Percentage Share Breakdown by Value Sales for Molecular Diagnostics Infectious Diseases, and Others......6
Cancer Drugs......7
Table 4: Oncology/Hematology Drugs Market by Category Worldwide (2015) - Percentage Share Breakdown by Value Sales for Blood Cell Factors, Chemopreventatives, Chemotherapeutics, Mabs, Targeted Therapies, and Others......7
Table 5: Oncology Drug Market by Region Worldwide (2015) - Percentage Share Breakdown by Value for European Union Five, Japan, US and Others......8
Cancer Market......9
Table 6: Cancer Care Expenditure by Site Worldwide (2015) - Percentage Share Breakdown for Breast, Colorectal, Lymphoma, Lung, Prostate and Others*......9
Table 7: Cancer Market by Category Worldwide (2015) - Percentage Share Breakdown by Value for Heme, Lung, Prostate, and Others......10
Table 8: Oncology Market by Cancer Type Worldwide (2015) - Percentage Share Breakdown by Value for Breast Cancer, Metastatic Colorectal Cancer, Non-Small Cell Lung Cancer, and Others......11
Table 9: Clinical Oncology Market by Region Worldwide (2015) - Percentage Share Breakdown by Value Sales for US, and Others......12
Table 10: Hereditary Oncology Market by Region Worldwide (2015) - Percentage Share Breakdown by Value Sales for US, and Others......13
Table 11: Cancer Market by Type in China (2015) - Percentage Share Breakdown by Value for Breast, Colorectal, Esophagus, Liver, Lung, Stomach and Others......14
Table 12: Oncology Market by Category in China (2015) - Percentage Share Breakdown by Value for Anti- Tumor Agents, Hormone Therapy, Immuno Suppresants and Immunostimulants......15
Table 13: Oncology Market by Segment in the US (2015) - Percentage Share Breakdown by Value for Solid Tumor and Others......16
Cancer Patients......17
Table 14: Breast Cancer Diagnoses by Hospital Type in the US (2015) - Percentage Share Breakdown by Volume for Community, Comprehensive, Teaching and Research, and Others......17
Table 15: No. of Colorectal Cancer Patients by Region Worldwide (2015) - Percentage Market Share Breakdown for Asia, Australia, Europe, and US......18
Table 16: No. of Invasive Breast Cancer Patients by Category Worldwide (2015) - Percentage Market Share Breakdown for Stage I and Stage II-III......19
Table 17: No. of Primary Liver Cancer Patients by Region Worldwide (2015) - Percentage Market Share Breakdown for Asia, Australia, Europe, and US......20
Table 18: No. of Chronic Lymphocytic Leukemia (CLL) (1L) Patients by Category Worldwide (2015) - Percentage Market Share Breakdown for Imbruvica PCYC, Rituxan, Gazyva ROG, and Others......21
Table 19: No. of Cutaneous Melanoma Patients by Region Worldwide (2015) - Percentage Market Share Breakdown for Asia, Australia, Europe, and US......22
Table 20: No. of Ocular Melanoma Patients by Region Worldwide (2015) - Percentage Market Share Breakdown for Asia, Australia, Europe, and US......23
Table 21: Female Mortality by Cancer Type in China (2015) - Percentage Market Share Breakdown by Volume for Lung, Breast, Colon, Rectum and Anus, Intestine, Liver, and Others......24
Table 22: Male Mortality by Cancer Type in China (2015) - Percentage Market Share Breakdown by Volume for Colon, Colon, Rectum and Anus, Intestine, Liver, Lung, and Others......25
Table 23: No. of Chronic Lymphocytic Leukemia (CLL) (1L) Patients by Category in European Union (2015) - Percentage Market Share Breakdown for Rituxan, Gazyva, and Others......26
Table 24: No. of Chronic Lymphocytic Leukemia (CLL) (R/R) Patients by Category in European Union (2015) - Percentage Market Share Breakdown for Rituxan, Gazyva, and Others......27
Table 25: No. of Cancer Patients by Type in the US (2015) - Percentage Market Share Breakdown for Colorectal Cancer (CRC), Melanoma, Non-Squamous Non-Small-Cell Lung Cancer (NSCLC), Ovarian, Prostate, Renal Cell Carcinoma (RCC), and Squamous Non-Small-Cell Lung Cancer (NSCLC)......28
Table 26: Number of Cancer Patients by Type in the US (2015) - Percentage Share Breakdown by Volume for Bladder Cancer, Breast Cancer (Female), Colon and Rectum Cancer, Endometrial Cancer, Kidney and Renal Pelvis Cancer, Lung and Bronchus Cancer, Melanoma of the Skin, Non-Hodgkin Lymphoma, Prostate Cancer, and Thyroid Cancer......29
Table 27: No. of Cancer Patients Death by Type in the US (2015) - Percentage Share Breakdown for Breast, Colorectal, Lung, Melanoma, and Prostate......30
Table 28: New Patients with Cancer by Site in the US (2015) - Percentage Market Share Breakdown by volume for Colorectal, Lung and Bronchus, Melanoma, Pancreas, and Others......31
Table 29: Number of Cancer Patients by Type Worldwide (2015) - Percentage Share Breakdown by Volume for Bladder, Breast, Cervix Uteri, Colorectum, Liver, Lung, Non-Hodgkin lymphoma, Oesophagus, Prostate, and Stomach......32
Table 30: No. of Bladder Cancer Patients by Category in the US (2015) - Percentage Market Share Breakdown for Invasive Patients, and Non-Invasive Patients......33
Table 31: No. of Invasive Breast Cancer Patients by Category in the US (2015) - Percentage Market Share Breakdown for Stage I and Stage II-III......34
Table 32: New Patients with Cancer in Stage 3/4 by Site in the US (2015) - Percentage Market Share Breakdown by Volume for Colorectal, Lung and Bronchus, Pancreas and Others......35
Table 33: No. of Solid Cancer Tumor Patients by Type Worldwide (2015) - Percentage Share Breakdown for Breast Cancer, Colorectal Cancer, Lung Cancer, Melanoma, and Prostate Cancer......36
Table 34: No. of Non Small Cell Lung Cancer Patients by Category in the US (2015) - Percentage Market Share Breakdown for Stage I, Stage II-III, Stage III-IV, and Undiagnozed......37
Cervical Cancer......38
Table 35: Cervical Cancer Market by HPV Type in England (2015) - Percentage Share Breakdown by Value for HPV 16, HPV 18, HPV 33, HPV 45, and Others......38
Table 36: Cervical Cancer Market by HPV Type in Europe (2015) - Percentage Share Breakdown by Value for HPV 16, HPV 18, HPV 31, HPV 33, and Others......39
Hematological Cancer......40
Table 37: Hematological Cancer by Category Worldwide (2015) - Percentage Market Share Breakdown by Value Sales for Chronic Lymphocytic Leukemia (CLL), Multiple Myeloma (MM), and Non-Hodgkin’s Lymphoma (NHL)......40
Skin Cancer......41
Table 38: Skin Cancer by Type Worldwide (2015) - Percentage Market Share Breakdown by Volume for Basal Cell Carcinomas, Melanoma, and Squamous Cell Carcinomas......41
Cancer-Associated Mucositis......42
Table 39: Cancer-Associated Mucositis Market by Activity Worldwide (2015) - Percentage Share Breakdown by Value for Breast, Colorectal, Head and Neck, Non-Small Cell Lung cancer and Others......42
Chronic Myelogenous Leukemia (CML)......43
Table 40: Chronic Myelogenous Leukemia (CML) Market by Region Worldwide (2015) - Percentage Share Breakdown by Value Sales for Asia-Pacific, Canada, European Union, Japan, USA, and Others......43
Multiple Myeloma......44
Table 41: Multiple Myeloma by Age Group Worldwide (2015) - Percentage Share Breakdown by No. of New Cases for 45-54, 55-64, 65-74, 75-84, >84, and Others......44
Table 42: Multiple Myeloma Market by Category Worldwide (2015) - Percentage Share Breakdown by Value Sales for Kyprolis AMGN, Pomalyst CELG, Revlimid CELG, Thalomid CELG, and Velcade TKD/JNJ......45
Anti-Cancer Drugs......46
Table 43: Anti-Cancer Drugs Market by Product Type in China (2015) - Percentage Share Breakdown by Value for Anastrozole, Capecitabine, Cetuximab, Compound kushen, Docetaxel, Epirubicin, Erlotinib, Gefitinib, Gemcitabine, Goserelin, Interferon α-2a, Interferon α-2b, Irinotecan, Kangai, Lentinan, Letrozole, Oxaliplatin, Paclitaxel, Pemetrexed, Pidotimod, RhG-CSF, RhIL-2, Rituximab, Sorafenib, Sshenqi Fuzheng, Thymopentin, Thymosin a1, Trastuzmmab, Triptorelin, TS-1, and Others......46
Table 44: Anti-Cancer Drugs Market by Type in China (2015) - Percentage Share Breakdown by Value for Alkylating Agents, Antibiotics, Antimetabolites, Hormonal Agents, Immunostimulant, Plant Alkaloids, and Others......47
Alzheimer Disease Therapeutics......48
Table 45: Market Shares of Leading Therapeutic Providers (Alzheimer's Disease, Bone Diseases, Cardiology, CNS, Dermatology, Diabetes/Metabolic, Epilepsy, G.I./Ulcer, HBV/HCV, Infectious Disease, Multiple Sclerosis, Obesity, Onc./Hematology, Ophthalmology, Orphan Disease, Pain Management, Respiratory, Rheumatology, Sleep Disorders, Urinary Incont., and Women's Health) by Value Sales Worldwide (2014) - Percentage Breakdown for AbbVie, Amgen, Inc., AstraZeneca Plc, Biogen Idec, Inc., Bristol-Myers Squibb Company, Eli Lilly and Company, Endo International Plc, F. Hoffmann-La Roche AG, Forest Laboratories, Inc., GlaxoSmithKline Plc, Johnson & Johnson, Merck Ltd., Novartis AG, Novo Nordisk A/S, Pfizer, Inc., Sanofi S.A., and Others......48
Table 46: Market Shares of Leading Alzheimer Disease Therapeutic Providers by Value Sales Worldwide (2014) - Percentage Breakdown for Forest Laboratories, Inc., Johnson & Johnson, Novartis International AG, Pfizer, Inc., and Others......49
Infectious Disease Drugs......50
Table 47: Market Shares of Leading Infectious Disease Drugs Manufacturers by Value Sales Worldwide (2014) - Percentage Breakdown for AbbVie, AstraZeneca Plc, Bristol- Myers Squibb Company, Eli Lilly and Company, F. Hoffmann-La Roche AG, Forest Laboratories, Inc., GlaxoSmithKline Plc, Johnson & Johnson, Merck Ltd., Novartis AG, Pfizer, Inc., Sanofi S.A., and Others......50
Cancer Drugs......51
Table 48: Market Shares of Leading Oncology Product Manufacturers Worldwide (2015) - Percentage Breakdown by Value for Fresenius SE & Co., and Others......51
Table 49: Market Shares of Leading Oncology/Hematology Therapeutic Providers by Value Sales Worldwide (2014) - Percentage Breakdown for AbbVie, Amgen, Inc., AstraZeneca Plc, Bristol-Myers Squibb Company, Eli Lilly and Company, F. Hoffmann-La Roche AG, GlaxoSmithKline Plc, Johnson & Johnson, Merck Ltd., Novartis AG, Pfizer, Inc., Sanofi S.A., and Others......52
Table 50: Market Shares of Leading Oncology Drug Manufacturers in China (2015) - Percentage Share Breakdown by Value for Astrazeneca, Jiangsu Hengrui Medicine Co., Ltd., Roche Group and Others......53
Breast Cancer Drugs......54
Table 51: Market Shares of Leading Breast Cancer Drugs by Value Sales in China (2014) - Percentage Breakdown for Alkylating Agents, Antimetabolite, Antitumor Antibiotics, Antitumor Antihormone, Antitumor Botanicals, Monoclonal Antibodies, Targeted Small Molecule Agents, and Others......54
Relapsed/Refractory (RR) Chronic Lymphocytic Leukemia (CLL)......55
Table 52: Market Shares of Leading Drugs for Treatment of Relapsed/Refractory (RR) Chronic Lymphocytic Leukemia (CLL) in the US (2015) - Percentage Share Breakdown by Value for Ibrutinib, Idelalisib and Others......55
Relapsed/Refractory (RR) Indolent Non-Hodgkin's Lymphoma (iNHL)......56
Table 53: Market Shares of Leading Drugs for Treatment of Relapsed/Refractory (RR) Indolent Non-Hodgkin's Lymphoma (iNHL) in the US (2015) - Percentage Share Breakdown by Value for Ibrutinib, Idelalisib and Others......56
Table 54: Market Shares of Leading Drugs for Treatment of Relapsed/Refractory Aggressive Non-Hodgkin Lymphoma (R/R- aNHL) in the US (2015) - Percentage Share Breakdown by Value for Ibrutinib and Others......57